Expression of human recombinant interleukin-1 receptor antagonist (rhIL-1ra) in E. coli with high efficiency
Di, Chung-Hui
Chinese Journal of Microbiology and Immunology 13(5): 285-287
1993
ISSN/ISBN: 0254-5101 Accession: 008661321
The cDNA coding for mature protein sequence of human interleukin-1 receptor antagonist (IL-1ra) was amplified from a lectin activated human peripheral mononuclear cell cDNA library with PCR technique. The purified PCR products were subcloned into a expression plasmid vector pKpL-3a and a clone expressing human recombinant IL-1ra with high efficiency was obtained.
PDF emailed within 1 workday: $29.90
Related References
Morris, O.; McMahon, A.; Boutin, H.; Grigg, J.; Prenant, C. 2016: Automation of [(18) F]fluoroacetaldehyde synthesis: application to a recombinant human interleukin-1 receptor antagonist (rhIL-1RA) Journal of Labelled Compounds and Radiopharmaceuticals 59(7): 277-283Clutterbuck, E.J.; Sanderson, C.J. 1990: Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor Blood 75(9): 1774-1779
Shen, J.; Gao, J.; Zhang, J.; Xiang, D.; Wang, X.; Qian, L.; Shen, J.; Yang, L.; Zhu, S.; Wu, M.; Yu, Y.; Han, W.; Wang, X. 2012: Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in mice Biomedicine and PharmacoTherapy 66(2): 83-88
Fujii, Y.; Imamura, M.; Hashino, S.; Kobayashi, H.; Kobayashi, M.; Kasai, M.; Sakurada, K.; Miyazaki, T. 1992: Therapy with cytokines and biological response modifiers brms prior to syngeneic bone marrow transplantation in mice effect of recombinant human interleukin 1 beta rhil 1 beta interleukin 2 rhil 2 interleukin 6 rhil 6 recombinant murine tumor necrosis factor alpha rmtnf alpha and chinese herbal medicine ninjin youei to nyt on immunohematologic reconstitution Biomedicine and Pharmacotherapy 46(5-7): 315
Bendele, A.; Colloton, M.; Vrkljan, M.; Morris, J.; Sabados, K. 1995: Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications Journal of Laboratory and Clinical Medicine 125(4): 493-500
Aoki, I.; Homori, M.; Nakahara, K.; Higashi, K.; Ishikawa, K. 1995: Effects of rhIL-1 alpha, rhIL-1 beta, and rhIL-1 receptor antagonist on erythroid progenitors (CFU-E and BFU-E) in human bone marrow Experimental Hematology 23(3): 217-225
Lazos, S.A.; Tsiftsoglou, A.S. 1998: Production and purification of recombinant human cytokines (rhIL-4, rhGM-CSF, and rhIL-1beta) from genetically engineered E. coli cells bearing pMAL expression vector constructs Journal of Protein Chemistry 17(6): 517
Singh, O.M.P.; Ray, K.P.; Ward, M.A.; Mackay, D.J.; Baines, B.S.; Bernard, A.R.; Weir, M.P. 1994: Simple high level purification of two related proteins, interleukin-1-beta and interleukin-1 receptor antagonist, produced by recombinant E coli Pyle, D L Separations for biotechnology 3 474-481
Steinkasserer, A.; Solari, R.; Mott, H.R.; Aplin, R.T.; Robinson, C.C.; Willis, A.C.; Sim, R.B. 1992: Human interleukin-1 receptor antagonist. High yield expression in E. coli and examination of cysteine residues Febs Letters 310(1): 63-65
Panegyres, P.K.; Hughes, J. 1998: The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene Journal of the Neurological Sciences 154(2): 123-132
Zanette, D.; Sarubbi, E.G.; Soffientini, A. 2003: Process for the purification of human interleukin-1 receptor antagonist from recombinant E coli Official Gazette of the United States Patent and Trademark Office Patents 1271(1)
Winton, E.F.; Srinivasiah, J.; Kim, B.K.; Hillyer, C.D.; Strobert, E.A.; Orkin, J.L.; Swenson, R.B.; McClure, H.M.; Myers, L.A.; Saral, R. 1994: Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model Blood 84(1): 65-73
Conti, P.; Feliciani, C.; Barbacane, R.C.; Panara, M.R.; Reale, M.; Placido, F.C.; Sauder, D.N.; Dempsey, R.A.; Amerio, P. 1992: Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells Immunology 77(2): 245-250
Fisher, C.J.; Dhainaut, J.F.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Shapiro, M.J.; Greenman, R.L. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase IIi rhIL-1ra Sepsis Syndrome Study Group JAMA 271(23): 1836-1843
Meyer, N.J.; Reilly, J.P.; Anderson, B.J.; Palakshappa, J.A.; Jones, T.K.; Dunn, T.G.; Shashaty, M.G.S.; Feng, R.; Christie, J.D.; Opal, S.M. 2018: Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration Critical Care Medicine 46(1): 21-28